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INTRODUCTION 
The incidence of hepatocellular carcinoma varies greatly with 
geographic location, ethnic background, and sex. For instance, incidence rates 
among men in sub-Saharan Africa and Asia may be 20 times higher than those 
among men in the United States (see the map). This disparity between countries 
is probably related to endemic rates of viral hepatitis and environmental 
carcinogens. 
        HCC frequently arises in the setting of cirrhosis, appearing 20-30 years 
following the initial insult to the liver. However, 25% of patients have no 
history or risk factors for the development of cirrhosis. The extent of hepatic 
dysfunction limits treatment options, and as many patients die of liver failure as 
from tumor progression. The prevalence of HCC worldwide parallels that of 
viral hepatitis and the majority of cases are associated with HBV and HCV. The 
increase in HCC incidence in the developed world is likely to be a direct result 
of the HCV epidemic occurring some 20–30 years after the rise in this infection 
in target populations. Alcohol, genetic hemochromatosis, and rarely primary 
biliary cirrhosis are associated9.  
     Although it is currently one of the most common worldwide causes of 
cancer death, a major impact on the incidence of HCC should be achieved 
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through current vaccination strategies for hepatitis B virus (HBV) infection, 
screening and treatment for hepatitis C virus (HCV) infections, and from the 
reduction of alcoholic liver disease. However, because the latency period from 
hepatic damage to HCC development is very long, it may be many years until 
the incidence of HCC decreases as a result of these interventions. 
      HCC is the fifth most common cancer in men and the eighth most common 
cancer in women worldwide. An estimated 560,000 new cases are diagnosed 
annually. The incidence of HCC worldwide varies according to the prevalence 
of hepatitis B and C infections. Areas such as Asia and sub-Saharan Africa with 
high rates of infectious hepatitis have incidences as high as 120 cases per 
100,000 populations9.    
    In India, though it is a relatively uncommon disease, some increase is 
suspected in South India. The Madras Metropolitan Tumour Registry (MMTR), 
a Population Based Cancer Registry, was established at the Cancer Institute 
(W.I.A) in 1981 in the network of National Cancer Registry Programme 
(NCRP) of Indian Council of Medical Research, New Delhi, to study the 
pattern and trend of Cancer incidence and mortality in Chennai City (formerly 
Madras).Recent reports from the registry (2001-2003) shows an incidence of 
liver cancer  about 2.5 per 100,000 male population ; 0.8 per 100,000 female 
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population. For Liver cancer, the relative proportion of cancers of all sites in 
men is 2.6%; female 0.8%18. 
  Reddy et al have reported an incidence of 1.6 per cent from Madras in an 
autopsy study of liver cell cancer. However, information regarding the clinical 
and virological profile of hepatocellular carcinoma in India is limited.   
 
 
 
Figure 1.High-15 per 100,000 populations per annum, Intermediate: 5 – 15 per 
100,000 populations per annum, Low: less than 5 per 100,000 populations per annum.  
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AIM OF STUDY 
 
1. To study the clinical & demographic pattern of hepatocellular carcinoma 
in our centre. 
2. To study the biochemical parameters &imaging characteristics of 
hepatocellular carcinoma.  
3. To analyze the virological pattern of HCC with the help of serology. 
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REVIEW OF LITERATURE 
 In adults in most parts of the world, hepatic metastases are more 
common than primary malignant tumors of the liver, although the converse is 
true in sub-Saharan Africa and parts of the Far East. HCC (Hepatocellular 
carcinoma) is an uncommon tumor in the Western world, where it represents 
only 0.5–2.0% of all cancers, and has an incidence of only three to five cases 
per 100,000 population per year in the United States, it has an attack rate as 
high as 150 per 100,000 population in areas of Sub-Saharan Africa and 
Southeast Asia. Worldwide, it is the most common visceral cancer and may be 
the single most common cancer21. 
 
EPIDEMIOLOGY: 
       The incidence of HCC varies dramatically around the globe, ranging 
from 150 cases per 100,000 population per year in areas such as Taiwan, 
Mozambique, and Southeast China to a low of three to seven cases per 100,000 
population in North and South America, North and Central Europe, and 
Australia. Intermediate rates from 5 to 20 cases per 100,000 population per year 
are found in Japan, the Middle East, and European countries bordering on the 
Mediterranean. The attack rate in Western developed countries is rising, 
however, with the incidence in the United States increasing by 71% between 
1976–1980 and 1991–1995. Similar changes have been noted in France, Italy, 
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the United Kingdom, Canada, Australia, and Japan. This increasing incidence is 
particularly linked to the rising numbers of patients with chronic hepatitis C. 
But Indian studies have shown the predominant association with Hepatitis B 
virus infections16. 
  Although these generalities hold true, marked differences can be seen 
within the same geographic area. Native black South Africans and native Maori 
males in New Zealand have attack rates 28- and 7-fold greater than whites in 
their respective countries. Blacks in Southern California have an attack rate four 
times greater than that of whites. Although the above findings suggest racial 
and/or genetic factors, environmental differences may play an even bigger role. 
It is commonly found that when natives move from areas with a high attack rate 
to one with a low attack rate, the incidence falls as they adapt the Western life-
style. In contrast, individuals who move from highly developed countries to 
third-world countries tend to retain their low attack rate, possibly because they 
maintain their original life-style rather than that of their adopted country. HCC 
is considerably more common in males (8:1 in areas of high incidence and 2:1 
to 3:1 in areas of low incidence)1. 
 
Race: 
HCC is most commonly found among Asians, due to childhood 
infections with hepatitis B. However, due to the implementation of childhood 
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hepatitis B vaccination programs in many Asian countries, a decrease in the 
incidence of HCC among Asians is expected9. 
Sex:  
HCC occurs more commonly in men than in women. In high-risk areas 
(China, sub-Saharan Africa, Japan), the difference between genders is more 
pronounced, with male-to-female ratios as high as 8:1. In industrialized 
countries, patients with hepatocellular carcinoma in the absence of cirrhosis 
have an approximately equal sex distribution9.  
Age:  
   The incidence of hepatocellular carcinoma increases progressively with 
advancing age in all populations, although it tends to level off in the oldest age 
groups. However, in ethnic Chinese and even more in black African 
populations, the mean age is definitely younger. This phenomenon is most 
striking in Mozambique, where more than 50% of Shangaan men with 
hepatocellular carcinoma are younger than 30 years of age, and their mean age 
is 33 years. Hepatocellular carcinoma is rare in children.Age at diagnosis varies 
widely according to geographic distribution. In the United States and Europe, 
the median age at diagnosis is 65 years. HCC is rarely diagnosed before age 40 
years. However, between 1975 and 1998, the 45- to 49-year age group had the 
highest rate, a 3-fold increase in the incidence of HCC1. 
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   In Africa and Asia, age at diagnosis is substantially younger, occurring 
in the fourth and fifth decades of life, respectively. Diagnosis at a younger age 
is thought to reflect the natural history of hepatitis B and C related HCC. 
 
PATHO PHYSIOLOGY: 
A number of factors have been associated with the pathogenesis of HCC, 
including physical, chemical, infectious, and metabolic/hereditary etiologies. 
This multistep model of hepatocarcinogenesis includes four steps. Initiation 
occurs when an infection or chemical exposure produces a fixed genetic change 
that makes the initiated cell responsive to promotion. During promotion, 
hepatocyte necrosis, inflammation with production of cytokines and growth 
factors, or exposure to specific chemicals (anabolic steroids, alcohol, iron) leads 
to liver regeneration and active or inactive cirrhosis. This “fixes” the genetic 
defect, preventing the liver from eliminating the cell with its altered genome. 
Progression occurs when these “growth-advantaged” malignant cells are 
stimulated to produce microscopic foci of HCC by clonal expansion. 
Phenobarbital and other chemicals are particularly effective in producing 
progression. Ultimately, continued growth stimulation and clonal expansion of 
the malignant cells lead to one or more macroscopic foci of HCC and clinically 
apparent cancer. Most explanations of hepatocellular carcinogenesis attempt to 
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recapitulate these steps and generally no single agent is felt to be sufficient by 
itself to induce HCC1. 
   The blend of risk factors differs in different parts of the world, and this 
may explain in part the diverse biologic characteristics of hepatocellular 
carcinoma in different populations. 
 
PHYSICAL AND CHEMICAL AGENTS 
1. Radiation:  
Ionizing radiation causes liver tumors in mice, but does not appear to be 
a significant factor in the development of human HCC. Long-term follow-up of 
those who survived the atomic bombing of Nagasaki and Hiroshima has not 
demonstrated an increase in HCC, although veno-occlusive disease and the 
Budd-Chiari syndrome are increased following radiation exposure. The low rate 
of cell turnover in the adult liver with the limited opportunity for fixation of 
genetic alterations may account for resistance to radiation-induced tumors. 
Long-term continuous exposure to radiation, however, can produce tumors in 
the human liver. The unfortunate use of thorotrast, one of the original radiologic 
contrast agents and the radionuclide of choice from the late 1920s to the mid-
1950s, has produced hemangiosarcomas and even HCCs. This a-radiation 
emitter has a biological half-life of approximately 400 years, and well over 
50,000 adults remain at risk for the development of HCC1.  
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2. Chemical carcinogenesis:  
Because of the liver's unique anatomic position in the body, and its dual 
blood flow, everything taken by mouth traverses the liver via the portal 
drainage of the abdominal viscera before reaching the systemic circulation. 
Compounds that enter the body via other routes also find their way to the liver, 
which receives 25% of the cardiac output. Over 12,350,000 unique chemical 
compounds have been identified and this total grows by more than 11,500 each 
week as new compounds are synthesized or found in the environment. Over 
90,000 are in regular use, including some 800 as food additives. In animal 
models, more than 3,000 chemicals are known to be carcinogenic and, as noted 
above, the rodent liver has been the standard model used to delineate the 
multistep model of hepatic carcinogenesis. Despite the overwhelming evidence 
of carcinogenicity of chemicals, and the massive daily exposure of the human 
liver to chemicals, only two chemicals are clearly documented human hepatic 
carcinogens: aflatoxin and vinyl chloride monomer.  
Aflatoxin B1  
Aflatoxin B1, derived from Aspergillus flavus and Aspergillus 
parasiticus, is an important risk factor for hepatocellular carcinoma in parts of 
Africa and Asia. A. flavus is ubiquitous in nature and contaminates a number of 
staple foodstuffs in tropical and subtropical regions. Epidemiologic studies have 
shown a strong positive correlation between the dietary intake of aflatoxin B1 
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and the incidence of hepatocellular carcinoma. Aflatoxin B1 and HBV may 
interact in the pathogenesis of hepatocellular carcinoma. One possible way in 
which aflatoxin B1 may contribute to hepatocarcinogenesis is suggested by the 
correlation between heavy dietary exposure to this mycotoxin and an 
inactivating mutation of the third base of codon 249 of the p53 tumor 
suppressor gene. It is the most powerful human hepatocarcinogen known and 
promotes tumors, in part, by leading to inactivation of p53 through specific G-T 
mutations at codon 249.  
Vinyl chloride monomer induces angiosarcomas in animal models as 
well as in industrial workers manufacturing polyvinyl chlorides. 
3. Viral and other infectious agents:  
There are many examples of virus-induced tumors in animal models. In 
most cases, the viral genome becomes incorporated into the host cells' genetic 
material either directly, if it is a DNA virus, or following reverse transcriptase 
production of a DNA copy, if it is an RNA virus. Insertion of the viral material 
into the host cell genome may then act as a mutagen or as a promoter to alter 
gene expression to produce new proteins, particularly oncogenes, or may cause 
over expression of normal genes, which leads to malignant transformation. The 
hepatitis B virus has the strongest association with the development of HCC 
and hepatitis B viral DNA has been found integrated into the genome of the 
host DNA in up to 80% of patients with HCC who are hepatitis B carriers. 
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However, there is no consistent site of integration. In contrast, hepatitis C, 
which is also strongly associated with HCC, is an RNA virus with no reverse 
transcriptase activity; thus, it is unlikely that it exerts its effect by insertion into 
the host cell genome. In Japan, where 70% of patients with HCC are hepatitis C 
positive, patients with chronic hepatitis C are three times more likely to develop 
HCC than those with chronic hepatitis B. Unlike in hepatitis B, however, HCC 
occurs only after the development of cirrhosis and the continuous 
necroinflammatory reaction with subsequent regeneration may account for its 
tumorigenic behavior27. 
4. Cirrhosis:  
Cirrhosis is a common feature in almost all cases of HCC. In some cases, 
such as hepatitis C, it may be the necroinflammatory reaction and continuous 
regeneration that ultimately “fix” the mutation that leads to malignant 
transformation and allows it to flourish. In other cases, such as hereditary 
hemachromatosis in which 3–27% of patients develop HCC, tumor develops 
only in patients with cirrhosis. If timely phlebotomy is performed in 
hemachromatosis prior to the development of cirrhosis, the lifelong risk of 
developing HCC is reduced to that of the normal population. 
However, cirrhosis is clearly only another cofactor in the development of HCC. 
In Western industrialized countries where HCC is uncommon, 80–90% of 
patients who develop HCC will have underlying cirrhosis and it occurs 
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primarily in older individuals. In contrast, in Africa, where chronic hepatitis B 
and aflatoxin exposure are common cofactors, HCC occurs at an earlier age, 
and only 60–70% of patients have underlying cirrhosis. A combination of 
hepatitis B with cirrhosis increases the risk of developing HCC by at least four-
fold over those who are hepatitis B negative. Virtually any form of cirrhosis 
appears to increase the risk of developing HCC, but the overall rates may vary 
from 40 to 50% in those with hepatitis B to 5 to 15% in those whose cirrhosis is 
caused by alcohol. The highest rate is found in hereditary tyrosinemia1. 
5. Drugs and alcohol:  
In the Western industrialized world, HCC is most commonly associated 
with alcohol. The lifetime risk of developing HCC appears to be about 15% in 
alcoholic cirrhosis, and this continues even after cessation of alcohol ingestion. 
In one study, 55% of patients who had stopped drinking had HCC at autopsy. 
As noted in the section on chemicals, many drugs act as initiators, promotors, or 
progression factors in the development of HCC in animals. Surprisingly few 
have been proven to produce HCC in humans. Possible exceptions are anabolic 
steroids and estrogens, which may play a role in the development of HCC, 
hepatic adenomas, and hemangiomas as discussed below. Phenobarbitol and 
diphenylhydantoin (Dilantin) are among the most potent promotors and 
inducers in animals, but have shown no association with HCC in humans. 
Similarly, tolazamide, oxytetracycline, and aminopyrine have not been 
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recognized as hepatic carcinogens in humans, despite their ability to be 
metabolized to carcinogenic nitrosamines. 
6. Genetic:  
Hereditary tyrosinemia has the clearest association with the development 
of HCC. Close to 40% of patients in one study developed HCC despite good 
dietary control. Tumors have also been reported in association with ataxia 
telangiectasia. Most other associations have not been borne out by more careful 
study, and convincing evidence of a genetic predisposition to the development 
of HCC is lacking. Familial clustering of HCC is seen in patients with chronic 
hepatitis B, but this is probably related to vertical and horizontal transmission 
of the hepatitis B. Differences between ethnic and geographic groups have been 
discussed above, and are probably more environmental than genetic. The 
association with Fanconi's anemia is probably related to the androgens used to 
treat the anemia rather than the underlying disease. Probably the best 
recognized and most striking association of a hereditary disease with the 
development of HCC is that with hereditary hemachromatosis. Hepatocellular 
carcinoma also may develop in patients with other inherited metabolic disorders 
that are complicated by cirrhosis, such as α1-antitrypsin deficiency and type 1 
hereditary tyrosinemia, whereas in patients with other diseases, for example 
type 1 glycogen storage disease, tumors develop in the absence of cirrhosis1. 
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   Hepatocellular carcinoma develops in as many as 45% of patients with 
hereditary hemochromatosis. Malignant transformation was thought to occur 
only in the presence of cirrhosis (and is certainly more likely to do so), but in 
recent years this complication has been reported in a few patients without 
cirrhosis. This observation suggests that excessive free iron in tissue per se may 
be carcinogenic, perhaps by generating mutagenic reactive oxygen species, a 
possibility that has gained further support from the observation that black 
Africans with dietary iron overload are at greatly increased risk of 
hepatocellular carcinoma. Hepatocellular carcinoma develops occasionally in 
patients with Wilson disease, but only in the presence of cirrhosis. Malignant 
transformation has been attributed to the cirrhosis but also may result from 
oxidant stress secondary to the accumulation of copper in the liver. 
   A statistically significant correlation between the use of oral 
contraceptive steroids and the occurrence of hepatocellular carcinoma has been 
demonstrated in countries in which the incidence of the tumor is low and there 
is no overriding risk factor for the tumor. This group of patients, however, 
constitutes a small proportion of all patients with hepatocellular carcinoma. The 
patients are usually relatively young. The increased risk persists for more than 
10 years after the agents are discontinued. Epidemiologic evidence of a link 
between cigarette smoking and the occurrence of hepatocellular carcinoma is 
conflicting, although most of the evidence suggests that smoking is a minor risk 
 16
factor. Heavy smokers have an approximately 50% higher risk than 
nonsmokers. The cytochrome P450 system, which is responsible for the 
metabolic activation of a number of chemical carcinogens, is highly inducible 
by smoking. 
  Hepatocellular carcinoma develops in about 40% of patients with 
membranous obstruction of the inferior vena cava, a rare congenital or acquired 
anomaly. Continuous cycles of hepatocyte necrosis followed by regeneration 
resulting from the severe and unremitting hepatic venous congestion render the 
cells susceptible to environmental mutagens and spontaneous mutations1. 
TABLE 1. 
 
S.No Etiological 
factors 
Incidence in HCC 
1. Cirrhosis 80 – 90 % 
2. HBV infection 80 % 
3. HCV infection 
  70-90 %( Japan), 
60-65 %(Italy), 
20 -50 %( US) 
 
PATHOLOGY 
 Definitive diagnosis of hepatocellular carcinoma depends on 
demonstrating typical histologic features. Suitable tissue samples generally can 
be obtained by percutaneous biopsy or fine-needle aspiration. The yield and 
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safety of the procedure can be increased by aiming the needle under 
ultrasonographic guidance. Laparoscopically directed biopsy is an alternative 
approach. Because there is a risk of local, regional, or systemic dissemination 
of hepatocellular carcinoma by needle biopsy or aspiration of the tumor, many 
clinicians believe that these procedures should be avoided if the tumor is 
thought to be operable1. 
Gross Appearance  
Hepatocellular carcinoma may take three forms—nodular, massive, or 
diffuse. The nodular variety accounts for about 75% of hepatocellular 
carcinomas and usually coexists with cirrhosis. It is characterized by numerous 
round or irregular nodules of various sizes scattered throughout the liver, some 
of which are confluent. The massive type is more common in younger patients 
with a noncirrhotic liver. It is characterized by a large circumscribed mass, 
often with small satellite nodules. This type of tumor is most prone to rupture. 
The diffusely infiltrating variety is rare. In this type, a large part of the liver is 
infiltrated homogeneously by indistinct minute tumor nodules, which may be 
difficult to distinguish from the regenerating nodules of cirrhosis that are almost 
invariably present. Hepatocellular carcinoma rarely, if ever, umbilicates. The 
tumor may be monoclonal (with intrahepatic metastases accounting for other 
tumor deposits) or polyclonal. 
 18
In the nodular and massive varieties, the tumor tissue is usually soft and 
bulges above the surrounding cut surface of the liver. Areas of necrosis and 
hemorrhage are common. Well-differentiated tumors are light brown, whereas 
anaplastic tumors are yellowish white or gray. Bile production may cause 
greenish brown discoloration of the tumor. The portal vein and its branches are 
infiltrated by tumor in up to 70% of cases seen at necropsy; the hepatic veins 
and bile ducts are invaded less often. 
Microscopic Appearance  
Hepatocellular carcinoma is classified histologically into well-
differentiated, moderately differentiated, and undifferentiated (pleomorphic) 
forms.  
Well-differentiated Appearance  
Despite the aggressive nature and poor prognosis of hepatocellular 
carcinoma, most tumors are well differentiated. Trabecular and acinar 
(pseudoglandular) varieties occur, sometimes in a single tumor. In the 
trabecular variety the malignant hepatocytes grow in irregular anastomosing 
plates separated by sinusoids lined by flat cells resembling Kupffer cells. The 
sinusoids may be inconspicuous, however. The trabeculae resemble those of 
normal adult liver, although they are often thicker and may be composed of 
several layers of cells. Scanty collagen fibers may be seen adjacent to the 
sinusoid walls. The malignant hepatocytes are polygonal, with abundant, 
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slightly granular cytoplasm that is less eosinophilic than that of normal 
hepatocytes. The nuclei are large and hyperchromatic with prominent nucleoli. 
Bile production is the hallmark of hepatocellular carcinoma, regardless of the 
pattern. 
A variety of glandlike structures are present in the acinar variety. They 
are composed of layers of malignant hepatocytes surrounding the lumen of a 
bile canaliculus, which may contain inspissated bile. A tubular or 
pseudopapillary appearance may be produced by degeneration and loss of cells, 
or cystic spaces may form in otherwise solid trabeculae. The individual cells 
may be more elongated and cylindrical than in the trabecular variety. 
Moderately Differentiated Appearance  
Solid, scirrhous, and clear cell varieties are described. In the solid 
variety, the cells are usually small, although they vary considerably in shape. 
Pleomorphic multinucleated giant cells are occasionally present. The tumor 
grows in solid masses or cell nests. Evidence of bile secretion is rare, and 
connective tissue is inconspicuous. Central ischemic necrosis is common in 
larger tumors. In the scirrhous variety, the malignant hepatocytes grow in 
narrow bundles separated by abundant fibrous stroma. Ductlike structures are 
occasionally present. In most tumors the cells resemble hepatocytes. In an 
occasional tumor, the malignant hepatocytes are predominantly or exclusively 
clear cells. More often, tumors contain areas of clear cells. The appearance of 
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these cells usually results from a high glycogen content, although in some cases 
fat is the cause. 
Undifferentiated Appearance  
The cells are pleomorphic, varying greatly in size and shape. The nuclei 
are also extremely variable. Large numbers of bizarre-looking giant cells are 
present. The cells may be spindle-shaped, resembling those of sarcomas. 
Globular hyaline structures may be seen in all types of hepatocellular 
carcinoma. These reflect the presence of α-fetoprotein, α1-antitrypsin, or other 
proteins. Mallory's hyaline is occasionally present. 
  Extrahepatic metastases are present at necropsy in 40% to 57% of 
patients with hepatocellular carcinomas. They are more common (70%) in 
patients without coexisting cirrhosis than in those with cirrhosis (30%). The 
most common sites are the lungs (up to 50% in some populations) and regional 
lymph nodes (20%). 
Fibro lamellar Hepatocellular Carcinoma  
This variant of hepatocellular carcinoma typically occurs in young 
patients, has an approximately equal sex distribution, does not secrete α-
fetoprotein, is not caused by chronic hepatitis B (HBV) or C (HCV) virus 
infection, and almost always arises in a noncirrhotic liver. Fibrolamellar 
hepatocellular carcinoma is more often amenable to surgical treatment and, 
therefore, generally has a better prognosis than conventional hepatocellular 
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carcinoma. It does not, however, respond to chemotherapy any better than other 
forms of hepatocellular carcinoma. The hepatocytes are characteristically 
plump and deeply eosinophilic and are encompassed by abundant fibrous 
stroma composed of thin, parallel fibrous bands that separate the cells into 
trabeculae or nodules. The cytoplasm is packed with swollen mitochondria and, 
in approximately half the tumors, contains pale or hyaline bodies. Nuclei are 
prominent, and mitoses are rare26. 
 
CLINICAL PRESENTATION: 
    HCC must always be suspected in a patient with rapid and dramatic 
change in previously stable cirrhosis. On routine visits, liver size (both and right 
and left lobes), the presence or absence of Ascites, numbers of spider 
angiomata, and degree of palmar erythema, as well as status of nutrition, 
muscle mass, and presence or absence of jaundice, should be recorded. 
Significant or rapid changes in any of these parameters, as well as the 
development of new symptoms or signs, should prompt the immediate search 
for possible development of HCC. Unfortunately, the disease is often clinically 
silent until it is well advanced or tumor diameter exceeds 10 cm9. 
 
History: Patients generally present with symptoms of advancing cirrhosis.  
• Pruritus 
• Jaundice 
 22
• Splenomegaly 
• Variceal bleeding 
• Cachexia 
• Low grade fever 
• Increasing abdominal girth (Rapid development of ascites) 
• Hepatic encephalopathy 
• Right upper quadrant pain  
 
Physical signs:  
• Jaundice 
• Ascites 
• Hepatomegaly 
• Alcoholic stigmata (Dupuytren’s contracture, spider angiomata) 
• Asterixis 
• Pedal edema 
• Periumbilical collateral veins 
• Enlarged hemorrhoidal veins 
 
Paraneoplastic Manifestations: 
The majority of paraneoplastic syndromes in hepatocellular carcinoma 
are rare. One of the more important is type B hypoglycemia, which occurs in 
fewer than 5% of patients and manifests as severe hypoglycemia early in the 
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course of the disease. Characteristically, the hypoglycemia is the reason that the 
patient seeks medical attention. Affected patients present with confusion, 
delirium, acute neuropsychiatric disturbances, convulsions, stupor, or coma. 
Not surprisingly, the presence of the underlying tumor is easily overlooked. 
Type B hypoglycemia is believed to result from the defective processing by 
malignant hepatocytes of the precursor to insulin-like growth factor II (pro-
IGF-II)1. 
  Another important paraneoplastic syndrome is polycythemia 
(erythrocytosis), which occurs in fewer than 10% of patients with 
hepatocellular carcinoma. If polycythemia develops in a patient known to have 
cirrhosis, hepatocellular carcinoma is highly likely. This syndrome is probably 
caused by the synthesis of erythropoietin by malignant hepatocytes. 
  A patient with hepatocellular carcinoma, especially the sclerosing 
variety, may present with hypercalcemia in the absence of osteolytic 
metastases. When hypercalcemia is severe, the patient is drowsy and lethargic 
and may be stuporous. The probable cause is secretion of parathyroid hormone-
related protein (PTHrP) by the tumor. Cutaneous manifestations of 
hepatocellular carcinoma are rare except for pityriasis rotunda, which may be a 
useful cutaneous marker of the tumor in black Africans. The disorder is 
characterized by single or multiple, round or oval, hyperpigmented scaly lesions 
on the trunk and thighs that range in size from 0.5 to 25 cm. 
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DIAGNOSIS: 
   Conventional tests of hepatic function do not distinguish hepatocellular 
carcinoma from other hepatic masses or from cirrhosis. Accordingly, they 
contribute little to the diagnosis of this tumor. Often the most striking 
laboratory finding in HCC is the lack of abnormal tests. Transaminases 
[aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] are 
most often normal or only minimally elevated. Alkaline phosphatase (AP) and 
g-glutamyltransferase are the most frequently abnormal tests, but are rarely 
more than two- to three-fold elevated. Lactate dehydrogenase (LDH) can be 
strikingly and disproportionately elevated in patients with metastatic liver 
disease, particularly if of hematogenous origin. 
Serum Tumor Markers  
Many of the substances synthesized and secreted by hepatocellular 
carcinoma are not biologically active. Nevertheless, a few are produced by a 
sufficiently large proportion of tumors to warrant use as serum markers of the 
tumor. The most helpful of these is α-fetoprotein. 
• Alpha-fetoprotein (AFP) is elevated in 75% of cases. 
o The level of elevation correlates inversely with prognosis. 
o An elevation of AFP greater than 400 ng/mL predicts for HCC 
with specificity greater than 95%. In the setting of a growing 
mass, cirrhosis, and the absence of acute hepatitis, many centers 
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use a level greater than 1000 ng/mL as presumptive evidence of 
HCC (without biopsy)9. 
α-Fetoprotein is a α1-globulin normally present in high concentration in 
fetal serum but in only minute amounts thereafter. Reappearance of high serum 
levels of α-fetoprotein strongly suggests the diagnosis of hepatocellular 
carcinoma (and hepatoblastoma). This finding is especially true in populations 
in which hepatocellular carcinoma is most prevalent: the great majority of 
ethnic Chinese and black African patients have a raised serum concentration 
(more than 20 ng/mL [20µg/L]), and about 75% have a diagnostic level (more 
than 500 ng/mL [500µg/L]). These percentages are lower in populations at low 
or intermediate risk of the tumor, and consequently, α-fetoprotein is a less 
useful tumor marker in these groups. The mean serum value of α-fetoprotein in 
affected patients in high incidence regions of hepatocellular carcinoma is 
60,000 to 80,000 ng/mL, compared with about 3000 ng/mL in regions with a 
low or intermediate incidence of the tumor. Raised serum values range over six 
orders of magnitude, although concentrations of greater than 1 million are rare. 
The reason 500 ng/mL (500µg/L) is used as a diagnostic level is that serum 
concentrations below this value may be found in patients with a variety of acute 
and chronic benign liver diseases, such as acute and chronic hepatitis and 
cirrhosis. False-positive results may also occur in patients with tumors of 
endodermal origin and undifferentiated teratocarcinomas or embryonal cell 
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carcinomas of the ovaries or testis. A progressively rising serum α-fetoprotein 
concentration, even if below the diagnostic level, is highly suggestive of 
hepatocellular carcinoma. 
    Because not all hepatocellular carcinomas produce α-fetoprotein, its 
presence is not essential to hepatocellular carcinogenesis, and there is no 
evidence that tumors that do not produce α-fetoprotein are biologically different 
from the majority of hepatocellular carcinomas. Synthesis of α-fetoprotein by a 
tumor is permanent and age-related: the younger the patient, the more likely the 
serum value is to be raised and the higher the level attained. Provided that 
patients are age-matched, there is no sex difference in α-fetoprotein production. 
No obvious correlation exists between the serum concentration of α-fetoprotein 
and any of the clinical or biochemical features of the tumor or the survival time 
after diagnosis. However, small presymptomatic tumors are associated with an 
appreciably lower serum level of α-fetoprotein than are symptomatic tumors. 
Attempts to correlate the degree of differentiation of hepatocellular carcinoma 
with production of α-fetoprotein have produced conflicting results. 
 Fucosylated α-Fetoprotein  
The α-fetoprotein secreted by malignant hepatocytes contains unusual 
and complex sugar chains that are not found in the α-fetoprotein present in the 
nontransformed hepatocytes. The sugar chains have the same core structure, but 
the number of the outer chain trisaccharides differs. This refinement is 
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particularly useful in the differential diagnosis of hepatocellular carcinoma 
when the serum α-fetoprotein concentration is less than 500 ng/mL [500 µg/L], 
and it may improve the diagnostic yield of α-fetoprotein in presymptomatic 
tumors. Unfortunately, the method now used to measure fucosylated α-
fetoprotein is rather complex and costly1. 
Des-γ-carboxy Prothrombin 
  Serum concentrations of des-γ-carboxy prothrombin (also known as 
prothrombin produced by vitamin K absence or antagonism II [PIVKA II]) are 
raised in the majority of patients with hepatocellular carcinoma. In populations 
in which the incidence of hepatocellular carcinoma is low, the abnormal 
prothrombin may prove to be a better marker than α-fetoprotein, and it could be 
used as a first-line tumor marker1. 
CA 125, tissue polypeptide antigen, and tumor-associated isoenzymes of 
5'-nucleotide phosphodiesterase have high sensitivity but poor specificity. 
Tumor-associated isoenzymes of γ-glutamyl transpeptidase and variant alkaline 
phosphatase have high specificity but low sensitivity, and both sensitivity and 
specificity are low for ferritin, carcinoembryonic antigen, CA 19-9, and 
calcitonin. 
  Two tumor markers—abnormal vitamin B12-binding protein and 
neurotensin—have been linked specifically to the fibrolamellar variant of 
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hepatocellular carcinoma. When present, they provide useful confirmatory 
evidence of this variant, but both markers have low sensitivity. 
TABLE 2 
Tumor markers Sensitivity Specificity 
Alpha-fetoprotein 80 – 90% 90% 
Des-γ-carboxy prothrombin 58 - 91 % 84 % 
α-L-Fucosidase 75 % 70 – 90% 
 
IMAGING: 
Liver imaging is done using ultrasonography, CT scanning, or MRI. 
When performed for suspected HCC due to a rising AFP, each test has a 70-
85% chance of finding a solitary lesion; sensitivity is higher with multiple 
tumors. Chest radiography may demonstrate pulmonary metastases1. 
Ultrasonography 
Ultrasonography detects the majority of hepatocellular carcinomas but 
does not distinguish this tumor from other solid lesions in the liver. Its 
advantages include safety, availability, and cost effectiveness, although it has 
the drawbacks of being nonstandardized and examiner-dependent. 
Approximately two thirds of symptomatic hepatocellular carcinomas are 
uniformly hyperechoic, whereas the remainder is partly hyperechoic and partly 
hypoechoic. Tumors located immediately under the right hemidiaphragm may 
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be difficult to detect. Ultrasonography with Doppler is useful for assessing the 
patency of the inferior vena cava, portal vein and its larger branches, hepatic 
veins, and biliary tree25. 
 Ultrasound is probably the most accurate imaging modality for 
visualizing small liver nodules, even compared with more advanced techniques 
such as helical CT, CT during arterial portography, digital subtraction 
angiography, CT arteriography, and T1/T2 weighted MRI. The probability of 
HCC undoubtedly increases when nodule diameter exceeds 10 mm 
(approximately 90%) but well over half (approximately 68%) of the smaller 
nodules we examined proved to be HCC and about 15% were considered to be 
premalignant. While Ultrasound and other imaging techniques (even the more 
advanced) are of limited use for the diagnosis of these small nodules, close to 
90% can be safely, rapidly, and reliably identified by means of US guided fine 
needle biopsy25. 
 
Computed Tomography  
Spiral (helical) CT and CT during arterial portography have greatly 
improved the diagnosis of hepatocellular carcinoma by CT. The images of 
hepatocellular carcinoma obtained with CT are, however, not specific. 
Nevertheless, CT is especially useful in defining the extent of the tumor within 
and beyond the liver and showing the course, caliber, and patency of blood 
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vessels. Because iodized poppy seed oil (Lipiodol) is concentrated and retained 
in hepatocellular carcinoma tissue, injection of this material at the end of 
hepatic arteriography can be used in conjunction with CT, performed after a 
suitable delay, to detect small tumors1. 
 
Magnetic Resonance Imaging  
MRI provides another way of distinguishing hepatocellular carcinoma 
from normal liver tissue. Most tumors have a low signal intensity on T1-
weighted images and a high signal intensity on T2-weighted images. Gradient-
echo sequences and turbo spin-echo sequences have greatly reduced the time 
needed for MRI. Furthermore, the use of a contrast agent, such as gadopentetate 
dimeglumine and superparamagnetic iron oxide, increases the accuracy of MRI, 
especially in detecting small hepatocellular carcinomas in cirrhotic livers and 
distinguishing small hepatocellular carcinomas from hemangiomas or 
dysplastic nodules discovered in surveillance programs1. 
Hepatic Angiography  
  Hepatic digital subtraction angiography is helpful in recognizing small 
hypervascular hepatocellular carcinomas but may miss early, well-differentiated 
hypovascular tumors. Dynamic contrast-enhanced ultrasonography with intra-
arterial infusion of CO2 microbubbles can be used to detect these hypovascular 
tumors and also to differentiate hepatocellular carcinoma from other hepatic 
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nodules. Angiography is also essential in delineating the hepatic arterial 
anatomy when planning surgical resection, transplantation, bland or 
chemoembolization of the tumor, or infusion of cytotoxic drugs directly into the 
hepatic artery or its branches1. 
 
LIVER BIOPSY: 
Core biopsy is favored over fine needle biopsy since larger amounts of 
tissue, often with normal surrounding parenchyma, can be obtained. Biopsy 
may be omitted in a clinical setting of a growing mass in a cirrhotic liver (>2 
cm) noted on 2 coincident imaging techniques with at least one imaging 
showing contrast enhancement. Likewise, a growing mass in a cirrhotic liver on 
one imaging modality with an associated AFP level greater than 500-1000 
ng/mL is clinically diagnostic of HCC. The need for biopsy should be carefully 
evaluated, especially if the risk for complications is high. Lesions that are 2-3 
cm or smaller may be dysplastic nodules in a cirrhotic background. These are 
probably premalignant, and obtaining a biopsy is especially important to 
distinguish them from HCC. Obtaining a biopsy may be unnecessary in patients 
who will undergo resection regardless of diagnosis or if definitely indicated 
then it will paramount to burn the tract to avoid seedling1. 
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Differential Diagnosis 
HCC must be distinguished from all of the other malignant and benign 
masses like Dysplastic nodules in cirrhosis, Fibrous nodular hyperplasia, 
Metastatic disease, Primary hepatic lymphoma. Usually the use of appropriate 
imaging studies, plus testing for α-fetoprotein, is sufficient. In fact, in a patient 
with cirrhosis with another risk factor such as hepatitis C, hepatitis B, 
hemochromatosis, or alcohol, the presence of a typical lesion on ultrasound and 
CT imaging, plus a high or rapidly rising a-fetoprotein, is sufficient to make the 
diagnosis without histological verification9. 
 
 
TREATMENT: 
1. Surgical resection: 
Resection or liver transplantation offers the best chance of cure for 
hepatocellular carcinoma. For resection to be considered, the tumor must be 
confined to one lobe of the liver and be favorably located, and ideally, the 
nontumorous liver tissue should not be cirrhotic. Resection can, however, be 
considered if the tumor is limited to the left lobe and the cirrhosis of the right 
lobe is not severe, or if the tumor is favorably located in either lobe, allowing 
the surgeon to perform a segmentectomy or limited nonanatomic resection. 
Overall, resection is feasible in only about 15% of patients. Resection carries an 
operative mortality rate of around 5% in noncirrhotic and 10% to 15% in 
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cirrhotic livers. One of the most disappointing aspects of resecting 
hepatocellular carcinoma is the very high recurrence rate. 
 
2. Radio frequency Ablation: 
 Radiofrequency ablation of HCC is a relatively newly described 
technique using a probe placed into the tumour mass, usually percutaneously. It 
uses high frequency ultrasound to generate heat at the probe tip which can 
destroy tissue. A single probe can destroy lesions of up to 3 cm and a multiple 
tipped probe has been used to target lesions of up to 6 cm in diameter. Larger 
tumours can be treated by radiofrequency ablation; the largest series is 126 
HCCs greater than 3 cm in diameter. Complete necrosis was produced in 47%. 
3. Chemotherapy  
 
Of chemotherapeutic agents, only doxorubicin (Adriamycin) has shown a 
better than 20% response rate. There have been essentially no cures with 
chemotherapy given systemically, either as a single agent or in combination. 
Site-directed chemotherapy via intraarterial perfusion has shown only a modest 
increase in response rate by allowing delivery of larger doses of 
chemotherapeutic agents directly to the tumor site. More promising, but 
primarily for short- or long-term palliation, is the recent approach of embolizing 
the vessels feeding the tumor with Gel foam or Lipiodol, an oily substance that 
becomes trapped in the tumor. An extension of these two approaches combines 
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embolization of the tumor vessels with chemotherapy, thus producing a 
combination of anoxic necrosis with high local concentrations of trapped 
chemotherapeutic agents. This approach with chemoembolization has shown 
some promise. For small tumors, less than 5 cm and preferably less than 3 cm 
in size, percutaneous ethanol, acetic acid, and even hot saline injections have 
proved quite beneficial in improving 3- to 5-year survival. 
4. Liver Transplantation: 
Liver transplantation is performed in patients in whom the tumor is not 
resectable but is confined to the liver or in whom advanced cirrhosis and poor 
liver function preclude resection. Orthotopic liver transplantation (OLT) can be 
considered for patients who meet the Milan criteria—one tumor less than 5 cm 
or up to 3 tumors all less than 3 cm. These highly selected patients have 
excellent survival rates, similar to those of patients who undergo liver 
transplantation for end-stage liver disease without HCC. OLT in combination 
with chemoembolization and post-transplant adjuvant chemotherapy have been 
reported to produce 5-year survival rates of 60–70% in highly selected patients. 
Prognosis 
The overall prognosis for HCC remains very poor. Mean survival after 
diagnosis of large tumors, if not treated, is less than 6 months. Small tumors 
have a considerably better prognosis, with one study reporting 90% survival at 
3 years in patients with tumors smaller than 3 cm; another found 63% survival 
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at 3 years in patients with tumors less than 5 cm in size, and Child– Pugh class 
A cirrhosis (compensated cirrhosis). Surgical resection of small tumors or 
possibly percutaneous ethanol injection or radiofrequency ablation provides the 
only reasonable chance for cure9. 
 
Guidelines for the diagnosis and treatment of hepatocellular carcinoma 
(HCC) in adults: (British society of Gastroenterology)  
Surveillance using abdominal ultrasound and α-fetoprotein (AFP) 
estimation can detect HCC of a smaller size than those presenting without 
screening. The only potentially curative therapies depend on detection of small 
HCC. If surveillance is offered, it should be six monthly abdominal ultrasound 
assessments in combination with serum AFP estimation.  
Diagnosis of HCC: 
The commonest clinical scenario is a patient with a mass discovered on 
ultrasound where AFP may or may not be raised. If the patient is known to have 
pre-existing cirrhosis and the mass is greater than 2 cm in diameter, there is a 
greater than 95% chance that the lesion is a HCC. If AFP is raised, this 
confirms the diagnosis and further investigation is only required to establish the 
most appropriate therapy. The normal range for AFP is 10–20 ng/ml and a level 
>400 ng/ml is usually regarded as diagnostic. Two thirds of HCCs less than 4 
cm however have AFP levels less than 200 ng/ml and up to 20% of HCC do not 
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produce AFP, even when very large. If AFP is normal, further radiological 
imaging (CT, MRI, or lipiodol angiography with follow up CT) will usually 
allow a confident diagnosis to be made and proceed to assessment of treatment 
without the need for biopsy. In the few cases where real diagnostic doubt 
persists, biopsy may be indicated. Using AFP testing also produces false 
positives; levels in the range 20–250 ng/ml are frequently seen in regenerating 
nodules in viral cirrhosis. A rising AFP over time, even if the level does not 
reach 400 ng/ml, is virtually diagnostic of HCC. 
      A focal lesion in the liver of a patient with cirrhosis is highly likely to be 
HCC. Initial assessment should be by spiral computed tomography (CT) of the 
liver (local spread) and thorax (metastases).Magnetic resonance imaging (MRI) 
with contrast enhancement or angiography with lipiodol injection and follow up 
CT may increase the accuracy of detection of other liver lesions. Biopsy is 
rarely required for diagnosis, and seeding of tumour in the needle tract occurs in 
1–3%. Biopsy of potentially operable lesions should be avoided where possible. 
Treatment of HCC: 
  The only proven potentially curative therapy for HCC remains surgical, 
either hepatic resection or liver transplantation, and patients with single small 
HCC (<5 cm) or up to three lesions <3 cm should be referred for assessment for 
these treatment modalities. 
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Liver transplantation should be considered in any patient with cirrhosis 
and a small (5 cm or less single nodule or up to three lesions of 3 cm or less) 
HCC. Patients with replicating HBV had a worse outlook due to HBV 
recurrence and were previously not considered candidates for transplantation. 
Effective antiviral therapy is now available and patients with small HCC, as 
defined above,should be assessed for transplantation.Hepatic resection should 
be considered as primary therapy in any patient with HCC and a non-cirrhotic 
liver (including fibro lamellar  variant).Resection can be carried out in highly 
selected patients with hepatic cirrhosis and well preserved hepatic function 
(Child-Pugh A) who are unsuitable for liver transplantation. Such surgery 
carries a high risk of postoperative decompensation and should be undertaken 
in units with expertise in hepatic resection and management of liver failure8. 
 
PREVENTION: 
Given the poor prognosis and lack of effective therapies for 
hepatocellular carcinoma, programs for prevention are desperately needed. 
Nonspecific measures to ensure sterile needles, safe laboratory practices, a 
clean donor blood supply, good general hygiene, effective public health policies 
and HBV vaccination should be every country's priority3. 
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PROGNOSIS: 
The prognosis of patients with hepatocellular carcinoma is assessed by 
the following methods: 
• Child-Turcotte-Pugh scoring system 
• Okuda staging 
• Cancer of the Liver  Italian program (CLIP) scoring system  
• Barcelona Clinic Liver Cancer (BCLC) staging  
Child scoring system can be used to assess the severity of any liver 
disease including hepatocellular carcinoma. Cirrhosis can also be staged 
clinically. A reliable staging system is the modified Child-Pugh classification 
with a scoring system of 5 to 15. This scoring system was initially devised to 
stratify patients into risk groups prior to undergoing portal decompressive 
surgery. The Child-Pugh score is a reasonably reliable predictor of survival in 
many liver diseases and predicts the likelihood of major complications of 
cirrhosis such as bleeding from varices and spontaneous bacterial 
peritonitis5,20,22. 
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Table 3. Child-Turcotte-Pugh scoring system5 
 
Table 4 – Child’s class         
Class Total points 
A 5 - 6 
B 7 - 9 
C 10 - 15 
 
   
Points scored for increasing abnormality 
Clinical and biochemical measurements 
1 2 3 
Albumin (g/dl) >3.5 2.8-3.5 <2.8 
Bilirubin (mg/dl) 1-2 2-3 >3 
For cholestatic diseases: Bilirubin (mg/dl) <4 4-10 >10 
PT (secs prolonged) 1-4 4-6 >6 
              Or 
INR <1.7 1.7-2.3 >2.3 
Ascites Absent Slight Moderate 
Encephalopathy (grade) None 1 and 2 3 and 4 
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 OKUDA staging: 
Tumour staging, which is the basis for therapeutic management, has 
traditionally been based on the Okuda system (table 19 ), which was developed 
18 years ago. At that time, early diagnosis of HCC was relatively rare, and the 
staging system was therefore based on data from patients with advanced 
disease11. 
Staging of HCC is based on four criteria: tumor size (<or > 50% of the 
liver), ascites (absent or present), bilirubin (< or > 3 mg/dL), and albumin (< or 
>3 g/dL) to establish Okuda stages I (no positive criteria), II (1or 2 positives), 
and III (3 or 4 positives). The Okuda system predicts clinical course better than 
the American Joint Cancer Commission TNM system. The natural history of 
each stage without treatment is as follows: stage I- 8 months; stage II-2 months; 
stage III-less than 1 month. 
 
Cancer of the Liver Italian program (CLIP) scoring system:  
The Cancer of the Liver Italian Program (CLIP) score is a newer staging 
system that has been validated in case series from various parts of the world. 
Although its predictive power has been found to be superior to that of the 
Okuda system in most cases, doubts have been raised regarding its value in 
certain populations11.  
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CLIP scoring system: 
Score of 0-2 is assigned for each of the 4 features listed below; 
cumulative score ranging from 0-6 is the CLIP score. 
 
1. Child-Pugh stage    :  Stage A = 0; Stage B = 1;   Stage C = 2 
 
2. Tumor morphology: 
     Uninodular and extension less than 50% = 0  
     Multinodular and extension less than 50% = 1 
    Massive and extension greater than 50% = 2 
 
3. Alpha-fetoprotein: Less than 400 = 0; Greater than 400 = 1 
 
4. Portal vein thrombosis: Absent = 0; Present = 1 
 
    Estimated survival based on CLIP score: Patients with a total CLIP score 
of 0 have an estimated survival of 31 months; those with score of 1, about 27 
months; score of 2, 13 months; score of 3, 8 months; and scores 4-6, 
approximately 2 months. The CLIP staging is simple, uses common clinical 
criteria, and is more accurate than the Okuda and Child-Pugh staging systems. 
Until a better system comes along it should be implemented as a useful staging 
system for HCC.  
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Barcelona Clinic Liver Cancer (BCLC) staging:  
   Among the prognostic variables considered in BCLC staging are 
performance status (PS) and portal hypertension, which are not taken into 
account in either the CLIP or Okuda system. These additional criteria should 
make it especially suitable for staging HCCs diagnosed early in patients with 
well compensated cirrhosis11,20,22. 
  Table 3 shows Definition of the Barcelona Clinic Liver Cancer (BCLC) 
staging for hepatocellular carcinoma. 
      Stages A and B: all criteria should be fulfilled. Stage C: at least one 
criterion; PST 1–2 or vascular invasion/ extra hepatic spread. Stage D: at least 
one criterion; PST 3–4 or Okuda stage III/ Child-Pugh C. 
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   Table 5: Definition of the Barcelona Clinic Liver Cancer (BCLC) staging 
for hepatocellular carcinoma11:  
Tumour status 
BCLC stage PST 
Tumour stage 
Okuda 
stage 
Liver function status 
Stage A: early HCC 0  I  
 A1 0 Single, <5 cm I 
No portal hypertension and 
normal bilirubin 
A2 0 Single, <5 cm I 
Portal hypertension and 
normal bilirubin 
A3 0 Single, <5 cm I 
Portal hypertension and 
abnormal bilirubin 
A4 0 3 tumours <3 cm I – II Child-Pugh A–B 
Stage B: 
intermediate HCC 
0 Large multinodular I – II Child-Pugh A–B 
Stage C: advanced 
HCC 
1 - 2 
Vascular invasion or 
extrahepatic spread 
I – II Child-Pugh A–B 
Stage D: end stage 
HCC 
3 - 4 Any III Child-Pugh C 
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MATERIALS AND METHODS 
This is a prospective observational study conducted in Government 
Rajaji Hospital, Madurai from July 2006 to April, 2007.  
All patients with clinical and biochemical evidence of cirrhosis were 
screened with Abdominal ultrasonogram and serum alpha-fetoprotein 
estimation.  
A total of 45 cases were selected for the study from department of 
Medicine, and department of Medical gastroenterology based on the following 
criteria proposed by British society of Gastroenterology. 
Inclusion criteria:  
      - All patients with histopathological evidence of hepatocellular 
carcinoma in Liver biopsy 
-Any patient with mass lesion (>2cm) in liver with 
• Serum Alpha-fetoprotein level more than 400ng/ml  
• Rising AFP levels even if the value is less than 400ng/ml 
 
Exclusion criteria: 
-  Any liver mass (<2cm) with normal alpha-fetoprotein level  
-  Any liver mass with primary malignancy of GIT, Testis, Breast, and  
    Lung 
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Patients with features of chronic liver disease were screened for 
Hepatocellular carcinoma by detailed clinical history taking& clinical 
examination. 
Patients with evidence of cirrhosis were subjected to Liver imaging to 
detect any mass lesion. In patients with liver mass, serum alpha-fetoprotein 
level (AFP) was done. Serum AFP level more than 400ng/ ml was considered 
diagnostic of HCC, irrespective of the size of liver mass. For those patients with 
AFP level <400ng/ ml, CT / MRI Abdomen was done to assess tumour 
characteristics. 
Patients with insignificant AFP levels and inconclusive imaging features 
were subjected to liver biopsy under ultrasound guidance. Liver biopsy was not 
done for mass lesion with features of resectability. 
Features of resectability are: single mass lesion confined to one lobe of 
liver in a cirrhotic liver, without vascular invasion and metastases. 
Following investigations were done: 
Complete Blood cell count 
Blood sugar, Urea, Creatinine 
Serum sodium, Potassium 
Serum bilirubin (Total, Direct, Indirect) 
SGOT, SGPT, Serum alkaline phosphatase 
Serum proteins, Albumin, Globulin 
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Serum Alpha-fetoprotein 
Liver imaging – Abdominal ultrasonogram, CT / MRI 
Upper GI endoscopy 
Liver biopsy in selected cases 
During Abdominal imaging, following features were noted: 
Liver size, Features of cirrhosis, Mass lesion (if any), Site of mass lesion 
(Lobe), Number of lesions, Size of lesion(s), Well-defined lesion or not, Portal 
vein invasion. 
 
  Complete virological profile was done for all cases. Markers for HBV 
infection (HBsAg, IgG Anti-HBc, HBeAg, HBV DNA), Markers for HCV 
infection (Anti-HCV antibodies, HCV RNA) were done and analyzed. 
Incidence of Chronic HBV infection, Chronic HCV infection, and Occult HBV 
infection were calculated. Occult HBV infection is present if HBsAg is 
negative, and HBV DNA is positive. 
 
Prognosis of the cases were assessed by Child-Pugh scoring system, 
Okuda staging.  
 
Consent     : Obtained  
Financial support    :  Nil 
Ethical committee clearance  :  Obtained   
Conflict of interest    : Nil 
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Statistical Tools  
 The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2002).Using this software, 
frequencies, percentage, mean, standard deviation, were calculated.  
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RESULTS 
  The results of clinical evaluation were shown below. The age 
distribution of the study is shown in Table No.6. 
TABLE 6 
AGE DISTRIBUTION 
                              Cases       
Age Group 
( in years) 
         Number         Percentage 
< 30 4 8.9 
31-40 1 2.2 
41-50 7 15.6 
51-60 19 42.2 
>60 14 31.1 
Total 45 100 
Mean 
Standard deviation 
55.1 yrs 
13 yrs 
 
The Mean age of patients in our study was 55.1 ± 13 yrs. Majority of 
patients were in sixth decade at the time of presentation. 
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TABLE 7 
SEX DISTRIBUTION 
                       Cases 
 
Sex 
No. % 
Males 40 88.9 
Females 5 11.1 
Total 45 100 
 
Table 7 shows sex distribution of the study. Majority of the patients were 
males. Male to female ratio was 8:1. 
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TABLE 8 
SYMPTOMS 
           Cases 
 
Symptoms  
No. % 
Fever 17 37.8 
Anorexia 36 80 
Nausea 15 33.3 
Vomiting 15 33.3 
Abdominal pain 41 91.1 
Hematemesis 10 22.2 
Pruritus  8 17.8 
Arthalgia 5 11.1 
Weight loss 29 64.4 
High coloured urine 23 51.1 
Clay coloured stool 10 20.8 
Malena 11 24.4 
 
  Table 8 shows list of clinical symptoms and its frequency in the study 
group. Commonest symptoms are abdominal pain, anorexia, weight loss, high 
coloured urine. Mean duration of symptoms was 6 months. 
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TABLE 9 
RISK FACTORS 
Cases                    Risk Factors     
      Number    Percentage (%)  
Alcohol use            20                      44  
Tobacco            25     55 
Oral contraceptives              0                           -       
Past H/o jaundice              5               11        
IV drug abuse              0                   - 
Multiple sex partners              4                     8      
Blood transfusion              3                 6        
 
    Table 9 shows risk factors for cirrhosis and hepatocellular carcinoma. 
All those alcohol users were males. Among tobacco users 23 were males; 2 
were females. The incidence of cirrhosis was 35% in the study. 
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TABLE 10 
 CLINICAL SIGNS 
Cases 
Signs present 
No. % 
Consciousness 
a) Conscious 
b) Drowsy 
c) Coma 
 
37 
7 
1 
 
82 
15 
2.2 
Pedal Edema 28 62 
Ascites 27 60 
Hepatomegaly 
i. Mild 
ii. Moderate 
iii. Massive 
 
14 
6 
17 
 
31 
13 
37 
Splenomegaly 
i. Mild 
ii. Moderate 
iii. Massive 
 
 
6 
3 
1 
 
13 
6 
2.2 
 
     Table 10 shows distribution of signs in the study group. Only one patient 
presented with hepatic encephalopathy.  
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TABLE 11 
HEMATOLOGICAL PARAMETERS 
PARAMETERS Mean S.D. 
Hemoglobin 9.24 2.26 
Urea 43.5 50.7 
Creatinine 1.1 0.6 
Bilirubin- Total 4.29 5.32 
Bilirubin- Direct 2.74 4.1 
Total protein 6.24 0.92 
Albumin 3.46 0.79 
Globulin 2.82 0.82 
SGOT(AST) 148.8 123.8 
SGPT(ALT) 74.5 79.6 
Alkaline phosphatase 409.9 297.2 
 
  Table 11shows hematological and biochemical parameters of the study 
group. Mean and standard deviation (S.D) of the parameters were calculated. 
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TABLE 12 
LABORATORY PARAMETERS 
CASES  
S.No Features Number Percentage (%) 
1. Anemia 42 93 
2. Elevated renal parameters 9 20 
3. Hypoglycemia 1 2.2 
4. Hyperbilirubinemia 33 73 
5. Hypoalbuminemia 18 40 
6. Raised Alkaline phosphatase 33 73 
 
  Table 12 shows hematological and biochemical parameter abnormalities 
in the study group. Anemia was the commonest abnormality detected with a 
mean Hb 9.2g/dl. 
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TABLE 13 
Upper GI Endoscopy 
S.No Findings Number (Total-34) Percentage (%) 
1. Normal 18 53 
2. Esophageal varices alone 9 26 
3. 
Esophageal varices + 
Portal hypertensive gastropathy 
7 21 
 
     Table 13 shows the upper gastro-intestinal endoscopy findings of the 
study group. Endoscopy was done in 34 patients. Esophageal varices were 
detected in 16 patients (47%).Portal hypertensive gastropathy was found in 7 
patients (21%).Upper GI endoscopy was normal in 18 patients (53%). 
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TABLE 14 
 IMAGING FEATURES 
Features No. % 
Cirrhosis 41 91 
Lobe involvement 
Right 
Left 
Both 
 
 
22 
3 
20 
 
 
49 
7 
44 
No. of Lesions 
Single 
Multiple 
 
 
22 
23 
 
 
49 
51 
Single Lesion - Size 
≤ 5 cm 
> 5 cm 
 
 
4 
18 
 
 
9 
40 
Multiple lesion- Size  
≤ 3 cm 
> 3 cm 
 
2 
21 
 
4 
47 
Portal vein Thrombosis 13 29 
Splenomegaly 12 26.7 
 
Table 14 shows the imaging characteristics of the study group. Incidence 
of cirrhosis in imaging was 91% with predominantly right lobe involvement.   
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TABLE 15  
VIRAL MARKERS 
S.No STATUS Number Percentage (%) 
1. HBV Infection 24 53 
2. HCV Infection 9 20 
3.  HBV & HCV Co-infection 1 2 
4. Occult HBV Infection 3 7 
5. 
HCV positivity among occult HBV 
infection 
0 - 
     
Table 15 shows the virological profile of the study group. Markers of 
HBV infection (HBsAg; Anti-HBc IgG), markers of HCV infection                   
(Anti-HCV; HCV RNA) were studied and the above conclusions were drawn. 
HBV infection was dominant among the study group (53%). 
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TABLE 16 
ALPHA-FETOPROTEIN 
S.No Serum alpha-fetoprotein Number (Total-38) Percentage (%) 
1. <10 ng / ml 6 16 
2. 10 – 400ng / ml 6 16 
3. >400ng/ml 26 68 
 
Table 16 shows serum alpha-fetoprotein pattern in the study group. 
Normal alpha-fetoprotein levels were found in 6 patients (16%). Insignificant 
values were found in 6 patients (16%). Significant diagnostic levels 
(>400ng/ml) were found in 26 patients (68%). 
TABLE 17 
LIVER BIOPSY 
S.No Biopsy findings Number (Total-19) Percentage (%) 
1. Positive for HCC  
   i) Classical HCC 
  ii) Fibro lamellar variant 
19 
18 
1 
 
95 
5 
2. Not suggestive of HCC - - 
 
Liver biopsy was deferred in 26 (57% of study group) patients for the 
following reasons: Poor general condition, prolonged prothrombin time, 
Operable tumors.  
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TABLE 18 
CHILD’S CLASSIFICATION 
S.No Child class Number of cases Percentage (%) 
1. A 21 46.6 
2. B 21 46.6 
3. C 3 6.7 
 
Table 18 shows staging of cases according to Modified child’s 
classification. Majority of patients were in Class A & B (93%) with equal 
distribution.  
TABLE 19 
OKUDA STAGING 
S.No Okuda Stage Number of cases Percentage (%)
1. 1 2 4.4 
2. 2 31 68.8 
3. 3 12 26.6 
 
 Table 19 shows classification of the study group according to okuda 
staging. Majority of patients were in stage 2 (68%).  
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DISCUSSION 
In western countries, numerous studies are being conducted in 
hepatocellular carcinoma. In India, the clinical trials regarding hepatocellular 
carcinoma are limited. Particularly, data on cancer epidemiology in southern 
parts of India is under-reported. To rectify this defect, Government has started a 
cancer registry in Tamil nadu. For southern parts of the Tamil nadu, a cancer 
registry is started in Dindugal. This is an attempt to emphasize the magnitude of 
the problem and to highlight the importance of early cancer screening program. 
 
  In this study, all the patients with features of cirrhosis, and any patient 
presented with a liver mass without the evidence of primary tumor were 
screened for the presence of hepatocellular carcinoma. More than 100 patients 
were screened and 45 among those were recruited for the study, based on the 
guidelines suggested by the British society of Gastroenterology (Published in 
“Gut “journal in 2003)8.  
 
   The study shows major occurrence of cases in sixth and seventh decade 
(See Table 6). About 19 cases (42%) are in the age group of 51- 60 years (sixth 
decade).  The mean age in this study is 55.1±13 yrs. The mean age of 
presentation depends on endemicity of HBV infection in the population. 
Population with high endemicity of HBV carrier state (Incidence>8%) shows 
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younger age of presentation. India comes under intermediate endemic region 
(4%) in this regard. There is an increase in incidence of HCC as the age 
advances in our study which is similar to many studies from literature. There 
are two patients in the adolescent age group17,27.  
 
  There is a male preponderance noted in this study which is supported by 
literature world wide. Proportion of male patients in the study group is 89%. 
The male to female ratio is 8: 1. It is found in the literature that male to female 
ratio may vary from 4:1 to 9:11.  
 
   Commonest symptoms found in our study are abdominal pain & 
swelling (91%), anorexia (80%), weight loss (64%), jaundice (51%), and fever 
(37%). The incidence of symptoms in our study is not different from the 
literature. 
 
   Commonest signs in our study are Hepatomegaly (81%), Ascites (60%), 
and Splenomegaly (21%) which are also not different from the literature. 
  
 The incidence of cirrhosis in our study (By imaging) is 91%, which is 
relatively higher than the incidence (80%) found in literature from western 
countries. In liver imaging, right lobe (49%) is involved more commonly than 
left lobe (7%) of the liver in our study1. 
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Number of lesions share relatively equal incidence. Among cases with 
single lesion (22 cases), only 3 patients (6% of study group) were suitable to 
undergo resection. Among patients with multiple lesions (23 cases), only one 
patient (2%) was suitable to undergo resection. The incidence of operable and 
inoperable cases in our study was 9% and 91% respectively. Features of 
resectability are single lesion (<5cm) confined to one lobe (preferably left lobe 
or right inferior segments) without vascular invasion and metastasis. Features of 
unresectable tumors are bi-lobar or four segmental involvement, portal vein 
thrombus, vena caval involvement or tumor thrombus. The incidence of portal 
vein invasion in our study is 29%. In literature, 35% cases of HCC show portal 
vein invasion4.      
 
The incidence of Chronic HBV and HCV infection in our study are 53% 
and 20% respectively, which is similar to other Indian studies. The incidence of 
occult HBV infection in our study is 7%, an important data which is often not 
found in many studies15,10. 
 
  
Serum alpha-fetoprotein levels were elevated in 32 patients (84%) in the 
study group. But, diagnostic levels (>400ng/ml) were found in 68% of cases. 
Data from western literature show that 80% of HCC cases have elevated alpha-
fetoprotein4. 
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   Liver biopsy was done in 19 cases where there was an unresectable liver 
mass with insignificant AFP elevation. Among 19 cases, only one fibro lamellar 
variety noted which was inoperable (multiple lesions >3cm) due to late 
presentation. Among 19 biopsy proven cases, 10 (53%) were positive for HBV 
infection; 3 cases (16%) were positive for HCV infection. The following table 
illustrates the relation between viral infection and alcoholism among biopsy 
proven cases. 
TABLE 20 
RISK FACTORS AMONG BIOPSY PROVEN HCC (19 CASES) 
S.No. Associated Risk factor Number of cases Percentage (%) 
1. HBV Positivity 10 53 
2. HCV Positivity 3 16 
3. Both HBV & HCV positive 0 - 
4. Total No. of Alcohol abuse 
   i) With HBV positivity 
  ii) With HCV positivity 
  iii) Without HBV& HCV 
8 
5 
1 
2 
42 
26 
5 
10 
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Prognostic scoring based on Child’s classification showed higher 
number of cases (46%) were in class A (compensated cirrhosis). Only patients 
in Child’s class A are suitable to undergo hepatic tumor resection. According to 
okuda staging, about 68% of cases were under stage 2. 
 
There are two Indian studies on clinical profile of hepatocellular 
carcinoma, which is comparable in most aspects. 
   
First study was from Department of Gastroenterology, GB Pant 
Hospital, New Delhi. about Profile of hepatocellular carcinoma in India10: 
 
Seventy-four consecutive cases of HCC were studied. A detailed history, 
tests for hepatitis B virus, hepatitis C virus infection, liver histopathology and 
HBV-DNA integration by using Southern blot hybridization were studied. 
Hepatocellular carcinoma patients were predominantly males (mean age 49.5 ± 
14.0 years). Portal hypertension and cirrhosis were seen in 56 (76%) patients. A 
majority (78.5%) of the chronic alcoholics had associated viral infection. The 
etiology of HCC remained undetermined in 15 (20%) patient. The conclusions 
of the study were: (i) HBV infection is the predominant factor for the 
development of HCC, often related to mutant forms of HBV; (ii) a majority of 
the HCC patients have overt cirrhosis of the liver; and (iii) HCV and alcohol 
per se are uncommonly associated. 
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  Another study was from Department of Hepatology, Postgraduate 
Institute of Medical Education and Research, Chandigarh on 2005.” Evaluation 
of clinical and biochemical parameters in hepatocellular carcinoma”15. 
 
Forty seven patients of HCC (Male = 43, Female = 4) diagnosed on the 
basis of history, clinical examination, imaging (USG, CT/MRI), α-fetoprotein 
(AFP) and by USG/CT guided FNAC, were included. Patients were screened 
for HBV, HCV and history of alcohol. Tumor size was assessed on imaging and 
UGI endoscopy for the presence of varices. The mean age was 53.4 ± 14.6 y. 
Clinical presentation included anorexia in 32 (68%), abdominal pain in 28 
(60%), loss of weight in 23 (49%), fever in 12 (26%), and jaundice in 6 (13%) 
patients. Seventeen percent had normal AFP (< 10 ng/ml) and the remaining 
83% had raised AFP [< 10 ng/ml = 7, 10–400 ng/ml = 27, > 400 ng/ml = 8]. 
Thirteen patients (28%) were consuming alcohol in cirrhogenic doses and 10 
(21%) were smokers. More than half of the HCC cases had underlying 
cirrhosis. Hepatitis B virus infection was commonly associated. Most of 
patients had a large tumor (> 5 cm) at presentation. This study results were 
similar to our study results. See the following table for comparison.  
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TABLE 21- Comparison Between Studies on HCC in India: 
 
S.No Features 
Our study(GRH) 
(2007) 
PGI study 
(2005) 
New Delhi 
(2001) 
1. Number of cases 45 47 74 
2. Male: female ratio 8:1 10:1 - 
3. Mean age 55.1 ± 13 yrs 
53.4 ± 
14.6yrs 
49.5 ± 14 
yrs 
4. Symptoms:    
 Abdominal pain 91 % 60 % - 
 Anorexia 80 % 68 % - 
 Weight loss 64 % 49 % - 
 Jaundice 51 % 13% - 
 Fever 37 % 26 % - 
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TABLE 22- Comparison Between Studies on HCC in India: 
S.No Risk factors 
Our 
study(GRH) 
(2007) 
PGI study 
(2005) 
New Delhi 
(2001) 
1. Cirrhosis 91 % 62 % 76 % 
2. Alcoholism 44 % 28 % - 
3. HBV infection 53 % 54 % 71% 
4. HCV infection 20 % 27 % 4 % 
5. 
Occult HBV 
infection 
7 % - - 
 
 
Current studies in various centre focus on therapeutic interventions for 
hepatocellular carcinoma. The findings of this preliminary study need 
confirmation from large multi-centric study. 
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CONCLUSIONS 
1. We conclude that hepatocellular carcinoma is not an uncommon 
malignancy in south India.  
 
2. Hepatocellular carcinoma has a Predominantly Male Preponderance. 
The major occurrence of HCC is in the sixth decade. 
 
3. Commonest symptoms found are abdominal pain & swelling, 
anorexia, weight loss, jaundice, and fever. 
 
4. Commonest signs are Hepatomegaly, Ascites, and Splenomegaly. 
Jaundice at presentation is not uncommon.  
 
5. Majority of cases of HCC occur in the background of cirrhosis. 
Nearly half of the patients present with esophageal varices.  
 
6. Commonest site of tumor is right lobe of the liver.  
 
7. Majority of cases are in decompensated stage of cirrhosis and 
inoperable at presentation. 
 
8. HBV infection is the leading cause of HCC in our study. The 
importance of occult HBV infection is also emphasized in this study. 
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9. Majority of cases present with significant elevation of alpha-
fetoprotein. This helps to make the diagnosis without the need for 
liver biopsy. 
 
10.  The clinical, biochemical and virological profile of hepatocellular 
carcinoma in south India is similar to data from north India.   
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SUMMARY 
BACKGROUND: 
 Hepatoma is a common malignancy seen in India. However, information 
regarding the clinical profile of hepatocellular carcinoma in India is limited. We 
decided to study the clinical profile of hepatoma cases in our centre. 
AIM: 
 To study the clinical, biochemical & imaging profile of hepatocellular 
carcinoma in our centre (Madurai medical college). 
METHODS: 
 All patients with histological evidence of hepatocellular carcinoma or 
clinical features of HCC with alpha-fetoprotein levels more than 400ng per dl 
were included in the study. A total of 45 cases from Govt. Rajaji hospital, 
Madurai were recruited. The duration of study was from July, 2006 to April, 
2007.The history, Clinical features, biochemistry, imaging, endoscopic 
findings, viral markers and prognostic scores (using okuda, Child) were 
analyzed. 
RESULTS: 
 The Mean age of patients in our study was 55.1 ± 13 yrs. Majority of 
patients were in sixth decade at the time presentation. Majority of the patients 
were males. Male to female ratio was 8:1. Commonest symptoms are 
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abdominal pain, anorexia, weight loss, high coloured urine. Only one patient 
presented with hepatic encephalopathy. Mean duration of symptoms was 6 
months. The incidence of cirrhosis was 91% in the study group. Anemia was 
found in 93% cases. Jaundice was noted in 73% of cases. The incidence of 
esophageal varices was 47%. Right lobe involvement was seen in nearly half 
the patients. The incidence of HBV and HCV infection is 53% and 20% 
respectively. Serum alpha-fetoprotein was elevated significantly (>400ng/ml) in 
68% cases. The incidence of operable and inoperable cases in our study was 9% 
and 91% respectively. 
CONCLUSION: 
• Hepatocellular carcinoma had a Predominantly Male Preponderance.  
• Major occurrence of cases in sixth decade. 
• The Lesions were unresectable at presentation in 91% cases.  
• HBV infection was the leading cause for HCC in the study. 
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A STUDY ON CLINICAL BIOCHEMICAL AND VIROLOGICAL 
PROFILE OF HEPATOCELLULAR CARCINOMA 
PROFORMA 
 
NAME:                                                                               AGE/SEX: 
WARD NO. /UNIT: 
ADDRESS:     
 
Date of Investigation: 
HISTORY: 
SYMPTOMS PRESENT / NOT DURATION 
 Fever   
 Loss of appetite   
 Abdominal pain   
 Abdominal swelling   
 Weight loss   
 Vomiting   
 Hematemesis    
 Melena    
 High coloured urine   
 Pruritus   
 Clay coloured stools   
 
RISK FACTORS: 
H/O Blood transfusion                                                                         YES / NO 
H/O Intravenous drug abuse                                                               YES / NO 
H/O Tattooing / Acupunture                                                         YES / NO 
H/O Long term dialysis                                                                        YES / NO 
H/O Any systemic illness                                                                     YES / NO 
H/O Any occupational exposure to blood products                             YES / NO 
H/O Multiple sexual partners                                                               YES / NO 
H/O Homosexuality                                                                               YES / NO 
H/O Use of any drugs for any systemic illness                                    YES / NO 
H/O Exposure to professional barbers                                                YES / NO 
H/O Other member of community being affected with jaundice          YES / NO     
H/O Jaundice in the past                                                                      YES / NO     
H/O Alcohol intake                                                                                YES / NO           
            If YES                        Currently / Occasionally / Former  
                                               Year of starting alcohol    : 
                                               Amount / (day/week)        :      
H/O Smoking / Tobacco chewing                                                          YES / NO     
H/O Oral contraceptive pill usage                                                          YES / NO           
H/O Similar illness in the family members 
CLINICAL ASSESSMENT: 
GENERAL EXAMINATION: 
      Level of consciousness:     Conscious& alert / Restless / Drowsy / Comatose 
      Built                                   Well built / Thin-built / Emaciated 
      Fever                                  YES / NO     
      Pallor                                  YES / NO 
      Icterus                                 YES / NO                            
      Clubbing                             YES / NO     
      Pedal edema                       YES / NO     
      JVP                                     Raised / Not raised 
      Purpurae                             YES / NO    
Signs of Alcoholism: 
      Palmar erythema                YES / NO                     
      Parotid enlargement           YES / NO     
      Spider naevi                       YES / NO   
      Dupuytren’s contracture    YES / NO 
Examination of ABDOMEN: 
        Inspection:  Normal contour / distended 
                           Engorged veins Present / Not 
                           Any Visible swelling   
        Palpation: Tenderness in any region 
                         Hepatomegaly   YES / NO    If yes   Mild / Moderate / Massive 
                         Hepatic bruit      YES / NO     
                         Splenomegaly    YES / NO    If yes   Mild / Moderate / Massive         
                         Ascites               YES / NO                                            
INVESTIGATIONS: 
BLOOD: 
Hemoglobin                      : 
WBC-Total count              : 
Differential count              : 
Platelet count                   : 
Glucose                            : 
Urea                                 : 
Creatinine                        : 
Serum Electrolytes          : 
Sodium                            : 
Potassium                       : 
Chloride                          : 
Bicarbonate                    : 
LIVER FUNCTION TESTS: 
Serum Bilirubin – Total   :  
Direct                              : 
Indirect                            : 
SGOT (AST)                   : 
SGPT (ALT)                    : 
Serum Proteins-  Total    : 
Albumin                           : 
Globulin                           : 
Serum Alkaline Phosphatase: 
   VIROLOGICAL PROFILE:   
       
S.No              MARKER                 STATUS 
 1. HBV  
    HBsAg  
    HBeAg  
    IgG Anti-HBc  
    HBV DNA  
 2. HCV  
   Anti-HCV  
   HCV RNA  
 
     Serum Alpha-fetoprotein : 
  
 
UPPER GI ENDOSCOPY: 
  Reg.no:                                                                          Date: 
      Oesophagus: 
      Stomach: 
      Duodenum: 
  Impression: 
 
 
LIVER IMAGING: 
Abdominal Ultrasonogram (USG):   
   Reg.no:                     Date: 
               
 
 
 
 
 
 
Computed Tomogram (CT):   
    Reg.no:                      Date:                    
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